Loading…

Neurotrophin receptor TrkB promotes lung adenocarcinoma metastasis

Lung cancer is notorious for its ability to metastasize, but the pathways regulating lung cancer metastasis are largely unknown. An in vitro system designed to discover factors critical for lung cancer cell migration identified brain-derived neurotrophic factor, which stimulates cell migration throu...

Full description

Saved in:
Bibliographic Details
Published in:Proceedings of the National Academy of Sciences - PNAS 2014-07, Vol.111 (28), p.10299-10304
Main Authors: Sinkevicius, Kerstin W., Kriegel, Christina, Bellaria, Kelly J., Lee, Jaewon, Lau, Allison N., Leeman, Kristen T., Zhou, Pengcheng, Beede, Alexander M., Fillmore, Christine M., Caswell, Deborah, Barrios, Juliana, Wong, Kwok-Kin, Sholl, Lynette M., Schlaeger, Thorsten M., Bronson, Roderick T., Chirieac, Lucian R., Winslow, Monte M., Haigis, Marcia C., Kim, Carla F.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lung cancer is notorious for its ability to metastasize, but the pathways regulating lung cancer metastasis are largely unknown. An in vitro system designed to discover factors critical for lung cancer cell migration identified brain-derived neurotrophic factor, which stimulates cell migration through activation of tropomyosin-related kinase B (TrkB; also called NTRK2). Knockdown of TrkB in human lung cancer cell lines significantly decreased their migratory and metastatic ability in vitro and in vivo. In an autochthonous lung adenocarcinoma model driven by activated oncogenic Kras and p53 loss, TrkB deficiency significantly reduced metastasis. Hypoxia-inducible factor-1 directly regulated TrkB expression, and, in turn, TrkB activated Akt signaling in metastatic lung cancer cells. Finally, TrkB expression was correlated with metastasis in patient samples, and TrkB was detected more often in tumors that did not have Kras or epidermal growth factor receptor mutations. These studies demonstrate that TrkB is an important therapeutic target in metastatic lung adenocarcinoma.
ISSN:0027-8424
1091-6490
DOI:10.1073/pnas.1404399111